Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

CYP2E1 RsaI/PstI Polymorphism and Liver Cancer Risk among East Asians: a Huge Review and Meta-analysis

  • Tian, Zhong (Department of General Surgery, Shengjing Hospital of China Medical University) ;
  • Li, Yi-Ling (Department of Gastroenterology, the First Affiliated Hospital of China Medical University) ;
  • Zhao, Lin (Department of General Surgery, Shengjing Hospital of China Medical University) ;
  • Zhang, Chen-Liang (Department of General Surgery, Shengjing Hospital of China Medical University)
  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Published data on any association between the CYP2E1 RsaI/PstI (c1/c2) polymorphism and liver cancer risk among east Asians are inconclusive. The aim of this Human Genome Epidemiology (HuGE) review and meta-analysis was to derive a more precise estimation of the relationship. A literature search of Pubmed, Embase, Web of science and CBM databases from inception through July 2012 was conducted. Twelve case-control studies were included with a total of 1,552 liver cancer cases and 1,763 healthy controls. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association under five genetic models. When all the eligible studies were pooled into the meta-analysis, the results showed that the c2 allele and the c2 carrier (c2/c2 + c2/c1) of RsaI/PstI polymorphism were associated with decreased risk of liver cancer among east Asians (c2 vs. c1: OR = 0.75, 95%CI: 0.59-0.95, P = 0.016; c2/c2 + c2/c1 vs. c1/c1: OR = 0.76, 95%CI: 0.58-1.00, P = 0.050). In the stratified analysis by country, significant associations were observed between RsaI/PstI polymorphism and decreased risk of liver cancer among the Chinese population (c2 vs. c1: OR = 0.70, 95%CI: 0.54-0.91, P = 0.007; c2/c2 + c2/c1 vs. c1/c1: OR = 0.72, 95%CI: 0.54-0.95, P = 0.020), but not among Japanese and Korean populations. Results from the current meta-analysis indicates that the c2 allele of CYP2E1 RsaI/PstI (c1/c2) polymorphism may be a protective factor for HCC among east Asians, especially among China populations.

Keywords

References

  1. Chandrasekaran K, Swaminathan K, Kumar SM, et al (2012). Increased oxidative stress and toxicity in ADH and CYP2E1 overexpressing human hepatoma VL-17A cells exposed to high glucose. Integr Biol (Camb), 4, 550-63. https://doi.org/10.1039/c2ib00155a
  2. Cheung C, Yu AM, Ward JM, et al (2005). The cyp2e1-humanized transgenic mouse: role of cyp2e1 in acetaminophen hepatotoxicity. Drug Metab Dispos, 33, 449-57.
  3. Chuang SC, Lee YC, Hashibe M, et al (2010). Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 19, 1261-8. https://doi.org/10.1158/1055-9965.EPI-09-1297
  4. da Costa BR, Cevallos M, Altman DG, et al (2011). Uses and misuses of the STROBE statement: bibliographic study. BMJ Open, 1, e000048. https://doi.org/10.1136/bmjopen-2010-000048
  5. Gonzalez FJ (2007). The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab Dispos, 35, 1-8.
  6. Harris RA, Chen G, Lin WY, et al (2003). Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population. Cancer Causes Control, 14, 995-1000. https://doi.org/10.1023/B:CACO.0000007984.79987.ec
  7. Hayashi S, Watanabe J, Kawajiri K (1991). Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem, 110, 559-65.
  8. He JH, Li YM, Zhang QB, et al (2011). Cyclooxygenase-2 promoter polymorphism -899G/C is associated with hepatitis B-related liver cancer in a Chinese population of Gansu province. Chin Med J (Engl), 124, 4193-7.
  9. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  10. Hirose Y, Naito Z, Kato S, et al (2002). Immunohistochemical study of CYP2E1 in hepatocellular carcinoma carcinogenesis: examination with newly prepared anti-human CYP2E1 antibody. J Nihon Med Sch, 69, 243-51. https://doi.org/10.1272/jnms.69.243
  11. Hu ZJ, Xue JF, Zhang XY, et al (2010). Relationship between genetic polymorphism of ERCC1 and susceptibility to liver cancer. Zhonghua Liu Xing Bing Xue Za Zhi, 31, 1288-91.
  12. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  13. Jiang AR, Wu JZ, Ding JH, et al (2004). Impact of CYP2E1 Rsa I polymorphism on risk of hepatocellular carcinoma. Chin J Cancer Prev Treat, 11, 464-6.
  14. Kato S, Onda M, Matsukura N, et al (1995). Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. Pharmacogenetics, 5 Spec No, S141-4. https://doi.org/10.1097/00008571-199512001-00016
  15. Kato S, Tajiri T, Matsukura N, et al (2003). Genetic polymorphisms of aldehyde dehydrogenase 2, cytochrome p450 2E1 for liver cancer risk in HCV antibody-positive japanese patients and the variations of CYP2E1 mRNA expression levels in the liver due to its polymorphism. Scand J Gastroenterol, 38, 886-93. https://doi.org/10.1080/00365520310004489
  16. Kirk GD, Bah E, Montesano R (2006). Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis, 27, 2070-82. https://doi.org/10.1093/carcin/bgl060
  17. Lai C, Shields PG (1999). The role of interindividual variation in human carcinogenesis. J Nutr, 129, S552-5.
  18. Lee HS, Yoon JH, Kamimura S, et al (1997). Lack of association of cytochrome P450 2E1 genetic polymorphisms with the risk of human hepatocellular carcinoma. Int J Cancer, 71, 737-40. https://doi.org/10.1002/(SICI)1097-0215(19970529)71:5<737::AID-IJC8>3.0.CO;2-S
  19. Lee SS, Buters JT, Pineau T, et al (1996). Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem, 271, 12063-7. https://doi.org/10.1074/jbc.271.20.12063
  20. Liu CZ, Bian JC, Shen FM, et al (2000). Genetic polymorphism of cytochrome P450 2E1 and susceptibility to hepatocellular carcinoma. Chin J Cancer, 5, 862-4.
  21. Lucas D, Ferrara R, Gonzales E, et al (2001). Cytochrome CYP2E1 phenotyping and genotyping in the evaluation of health risks from exposure to polluted environments. Toxicol Lett, 124, 71-81. https://doi.org/10.1016/S0378-4274(00)00287-3
  22. McGlynn KA, London WT (2012). International liver cancer incidence trends--letter. Cancer Epidemiol Biomarkers Prev, 21, 384-5; author reply 6. https://doi.org/10.1158/1055-9965.EPI-11-1102
  23. Munaka M, Kohshi K, Kawamoto T, et al (2003). Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol, 129, 355-60. https://doi.org/10.1007/s00432-003-0439-5
  24. Parkin DM (2006). The global health burden of infectionassociated cancers in the year 2002. Int J Cancer, 118, 3030-44. https://doi.org/10.1002/ijc.21731
  25. Perz JF, Armstrong GL, Farrington LA, et al (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol, 45, 529-38. https://doi.org/10.1016/j.jhep.2006.05.013
  26. Peters JL, Sutton AJ, Jones DR, et al (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676-80. https://doi.org/10.1001/jama.295.6.676
  27. Ruiz J, Sangro B, Cuende JI, et al (1992). Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology, 16, 637-41. https://doi.org/10.1002/hep.1840160305
  28. Settels E, Bernauer U, Palavinskas R, et al (2008). Human CYP2E1 mediates the formation of glycidamide from acrylamide. Arch Toxicol, 82, 717-27. https://doi.org/10.1007/s00204-008-0296-8
  29. Sheng Y, Huang TR, Zhang ZQ, et al (2009). Study on the relationship between familial clustering of hepatocellular carcinoma and polymorphism of cytochrome P450 2E1 gene in Guangxi Zhuang population. Zhonghua Liu Xing Bing Xue Za Zhi, 30, 151-5.
  30. Tanaka E, Terada M, Misawa S (2000). Cytochrome P450 2E1:its clinical and toxicological role. J Clin Pharm Ther, 25, 165-75. https://doi.org/10.1046/j.1365-2710.2000.00282.x
  31. Wang AH, Zhu SM, Qiu YL, et al (2008). CYP2E1 mRNA expression, genetic polymorphisms in peripheral blood lymphocytes and liver abnormalities in Chinese VCMexposed workers. Int J Occup Med Environ Health, 21, 141-6.
  32. Wang S, Zhang QY, Zhou RL (2012). Relationship between LAPTM4B gene polymorphism and susceptibility of primary liver cancer. Ann Oncol, 23, 1864-9. https://doi.org/10.1093/annonc/mdr538
  33. Wu XH, Yang XY, Duan W, et al (2007). The relationship between genetic polymorphism of cytochrome P450 and susceptibility to hepatocellular carcinoma. Acta Academic Medicine CPAPF, 16, 47-8.
  34. Yan QG, Shi JG, Zhang F, et al (2008). Overexpression of CYP2E1 enhances sensitivity of hepG2 cells to fas-mediated cytotoxicity. Cancer Biol Ther, 7, 1280-7. https://doi.org/10.4161/cbt.7.8.6283
  35. Ye XP, Peng T, Liu TW, et al (2008). The effect of interaction between alcohol drinking and polymorphisms of cytochrome P450 2E1 on the susceptibility of hepatocellular carcinoma in Guangxi region. J Guangxi Med Univ, 25, 493-5.
  36. Yu MW, Gladek-Yarborough A, Chiamprasert S, et al (1995). Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology, 109, 1266-73. https://doi.org/10.1016/0016-5085(95)90587-1
  37. Yu SZ, Huang XE, Koide T, et al (2002). Hepatitis B and C viruses infection, lifestyle and genetic polymorphisms as risk factors for hepatocellular carcinoma in Haimen, China. Jpn J Cancer Res, 93, 1287-92. https://doi.org/10.1111/j.1349-7006.2002.tb01236.x
  38. Zhang L, Liu JL, Zhang YJ, et al (2011). Association between HLA-B*27 polymorphisms and ankylosing spondylitis in Han populations: a meta-analysis. Clin Exp Rheumatol, 29, 285-92.
  39. Zhang S, Liu S, Liu H, et al (2000). Genotyping cytochrome P450IIE1 in alcoholic liver diseases and its significance. Zhonghua Gan Zang Bing Za Zhi, 8, 338-9.
  40. Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol, 28, 123-37. https://doi.org/10.1002/gepi.20048

Cited by

  1. Functional RsaI/PstI Polymorphism in Cytochrome P450 2E1 Contributes to Bladder Cancer Susceptibility: Evidence from a Meta-analysis vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4977
  2. A regulatory variant in CYP2E1 affects the risk of lung squamous cell carcinoma vol.35, pp.1, 2014, https://doi.org/10.1007/s13277-013-1063-x
  3. Liver cancer-related gene CYP2E1 expression in HBV transgenic mice with acute liver injury vol.35, pp.4, 2014, https://doi.org/10.1007/s13277-013-1486-4
  4. Toxicological implications of mitochondrial localization of CYP2E1 vol.6, pp.3, 2017, https://doi.org/10.1039/C7TX00020K
  5. Cytochrome P450 Genes (CYP2E1 and CYP1A1) Variants and Susceptibility to Chronic Hepatitis B Virus Infection pp.0974-0422, 2017, https://doi.org/10.1007/s12291-017-0698-6